Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $41.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
